



SPECIAL ARTICLE

Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!



Niki Katsiki^{a,*}, Anca Pantea Stoian^b, Manfredi Rizzo^{c,d}

^a First Department of Internal Medicine, Diabetes Center, Division of Endocrinology and Metabolism, AHEPA University Hospital, Thessaloniki, Greece

^b Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

^c Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy

^d Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, SC, USA

Received 22 October 2021; accepted 26 October 2021

KEYWORDS

Non-alcoholic fatty liver disease;
Mediterranean diet;
Dietary Approaches to Stop Hypertension diet;
Vegetarian diet;
Ketogenic diet;
Intermittent fasting;
Paleo diet

Abstract Non-alcoholic fatty liver disease (NAFLD) is the most frequent hepatic disease globally. NAFLD patients are at an increased risk of both liver and cardiovascular morbidity and mortality, as well as all-cause death. NAFLD prevalence is rapidly increasing worldwide and, thus, there is an urgent need for health policies to tackle its development and complications. Currently, since there is no drug therapy officially indicated for this disease, lifestyle interventions remain the first-line therapeutic option.

In the present narrative review, we discuss the effects of certain dietary patterns on NAFLD incidence and progression. The Mediterranean diet is regarded as the diet of choice for the prevention/treatment of NAFLD and its complications, based on the available evidence. Other plant-based dietary patterns (poor in saturated fat, refined carbohydrates, red and processed meats) are also beneficial [i.e., Dietary Approaches to Stop Hypertension (DASH) and vegetarian/vegan diets], whereas more data are needed to establish the role of ketogenic, intermittent fasting and paleo diets in NAFLD.

Nevertheless, there is no ‘‘one-size-fits-all’’ dietary intervention for NAFLD management. Clinicians should discuss with their patients and define the diet that each individual prefers and is able to implement in his/her daily life.

© 2021 Sociedad Española de Arteriosclerosis. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: nikikatsiki@hotmail.com (N. Katsiki).

PALABRAS CLAVE

Enfermedad de hígado graso no alcohólico;
Dieta mediterránea;
Dieta de enfoques alimentarios para detener la hipertensión;
Dieta vegetariana;
Dieta cetogénica;
Ayuno intermitente;
Dieta paleo

Patrones alimentarios en la enfermedad del hígado graso no alcohólico (EHGNA): ¡siga por el buen camino!

Resumen La enfermedad de hígado graso no alcohólico (EHGNA) es la enfermedad hepática más frecuente a nivel global. Los pacientes de EHGNA tienen un riesgo incrementado de morbilidad y mortalidad hepática y cardiovascular, y muerte por cualquier causa. La prevalencia de EHGNA se está incrementando rápidamente a nivel mundial, y por tanto existe una necesidad urgente de políticas sanitarias para afrontar su desarrollo y complicaciones. Actualmente, dado que no existe ninguna terapia farmacológica indicada de manera oficial para esta enfermedad, las intervenciones sobre el estilo de vida siguen siendo la opción terapéutica de primera línea.

En la revisión de la narrativa actual debatimos los efectos de ciertos patrones alimentarios en la incidencia y progresión de EHGNA. La dieta mediterránea se considera la dieta de elección para la prevención/tratamiento de EHGNA y sus complicaciones, sobre la base de la evidencia disponible. Otros patrones alimentarios basados en plantas (bajos en grasas saturadas, hidratos de carbono refinados, carnes rojas y procesadas) son también beneficiosos —es decir, DASH (*Dietary Approaches to Stop Hypertension* [Enfoques alimentarios para detener la hipertensión]) y dietas vegetarianas/veganas—, aunque se necesitan más datos para establecer el papel de las dietas cetogénicas, de ayuno intermitente y paleo en la EHGNA.

Sin embargo, no existe una intervención alimentaria «universal» para el manejo de EHGNA. Los clínicos deberán debatir con sus pacientes y definir la dieta que prefiera cada individuo, y que este pueda introducir en su vida diaria.

© 2021 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the major cause of hepatic disease worldwide, affecting over 25% of the general population.¹ The prevalence of NAFLD is further increased in obese individuals and patients with type 2 diabetes (T2D).² Histologically, NAFLD begins as simple steatosis (i.e., >5% liver fat accumulation without inflammation) and can progress to the more severe form of non-alcoholic steatohepatitis (NASH) (with inflammation, necrosis, ballooning and fibrosis), potentially leading to liver cirrhosis, hepatocellular carcinoma and end-stage liver disease.³ Apart from liver morbidity and mortality, NAFLD/NASH patients have also an increased cardiovascular (CV) risk, with more patients dying from a CV event than a liver-related cause.³

Taken into consideration that the epidemic of obesity and T2D is constantly increasing globally, NAFLD prevalence is also increasing proportionately.² Therefore, there is an urgent need to tackle this tremendous clinical and economic burden by preventing and/or treating NAFLD/NASH. Although there are some drugs (e.g., hypolipidemic and antidiabetic) that have been reported to improve the biochemical and histological features of NAFLD/NASH,^{4–7} there is currently no drug therapy officially approved for this disease and thus, lifestyle interventions remain the first-line therapeutic option. Nutrition research is now focusing on healthy dietary patterns (and not on single nutrients or specific foods) to identify the optimal diets for chronic disease prevention.⁸ In the present narrative review, we discuss the effects of certain dietary patterns on NAFLD/NASH incidence and progression.

Mediterranean diet (MedDiet) and NAFLD

MedDiet is the most widely studied dietary pattern in scientific literature, found to exert, apart from weight loss, several other health benefits such as improvements in oxidative stress and inflammatory markers, insulin sensitivity, glucose and lipid metabolism, endothelial and antithrombotic function.^{9–11} These beneficial effects of the MedDiet have been largely attributed to certain dietary components, including monounsaturated fatty acids (mainly olive oil), polyunsaturated fatty acids (from nuts, seed and fish), as well as plant-based foods (such as vegetables, legumes and fruits). A higher adherence to the MedDiet has been related to lower risks of all-cause mortality, CV morbidity and death, metabolic diseases and cancer.⁹ MedDiet is considered for the prevention of cardiometabolic and degenerative diseases, focusing on its beneficial impact as a holistic dietary approach.¹² In this context, it has been shown that adherence to the MedDiet can lower the risk of developing NAFLD.¹³

Several cross-sectional and randomized clinical trials have been conducted to test the effects of MedDiet in NAFLD/NASH patients, as reviewed elsewhere.^{14,15} In these trials, MedDiet was reported to reduce weight, BMI, BP, oxidative stress, inflammation, insulin resistance, fasting glucose and lipids, as well as NAFLD score, intrahepatic fat content, liver tests, hepatic steatosis, stiffness and fibrosis and NAFLD severity and progression.^{16,17} Of note, the hepatometabolic benefits induced by the MedDiet are independent of weight loss.¹⁸ In meta-analyses involving NAFLD patients, implementation of the MedDiet was shown to improve weight, insulin resistance, dyslipidemia, liver tests,

steatosis and NAFLD severity indices, as well as to decrease overall mortality and morbidity.^{15,19–22}

Based on the above, MedDiet is recommended in individuals with NAFLD/NASH, since it can improve both liver steatosis and several CV risk factors, thus also protecting from CV morbidity/mortality.²³ Indeed, current guidelines, including the National Institute for Health and Care Excellence (NICE)²⁴ and the joint recommendation from the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD) and the European Association for the Study of Obesity (EASO),²⁵ strongly support the implementation of MedDiet in NAFLD/NASH patients.

Overall, the MedDiet is superior to other diets in preventing/treating NAFLD/NASH, as well as MetS and its components, T2D and CVD.¹⁸ Furthermore, MedDiet is easier to follow and has greater scientific evidence for cardiometabolic benefits compared with other dietary patterns. Therefore, it is recommended as the diet of choice for the prevention/treatment of NAFLD/NASH and its complications.

Dietary Approach to Stop Hypertension (DASH) diet and NAFLD

DASH diet has been shown to significantly reduce body weight, BP, LDL-C, total cholesterol and HbA1c, as well as protect against CVD and T2D incidence, thus representing an attractive option for overweight/obese patients.^{26,27} There is also some evidence on DASH diet-induced benefits in NAFLD patients.²⁸ In this context, in a cross-sectional analysis of the Guangzhou Nutrition and Health Study (a population-based cohort study, involving 3051 participants), adherence to the DASH diet (defined by higher DASH diet score) was independently associated with a significantly lower prevalence of NAFLD, as well as with reduced levels of inflammation, insulin resistance and BMI.²⁹ A similar inverse relationship between the DASH diet and the risk of NAFLD was reported in a case-control study with 102 NAFLD patients (diagnosed by transient elastography) and 204 controls,³⁰ as well as in a nested case-control analysis of the Multiethnic Cohort (MEC) [$n=2959$ NAFLD cases (509 with cirrhosis) and 29,292 controls].³¹ In the latter study, the inverse association was even greater for NAFLD patients with than those without cirrhosis.³¹ Apart from NAFLD risk, DASH score has also been inversely associated with liver fat content (measured by MRI) in a cross-sectional study of 136 non-diabetic non-smokers individuals.³²

In a randomized controlled trial ($n=60$ overweight/obese NAFLD patients, diagnosed by ultrasonography and increased ALT levels), implementation of the DASH diet for 8 weeks was reported to significantly improve weight, BMI, ALT, insulin resistance and TG, as well as markers of inflammation and oxidative stress compared with the control diet.³³

Overall, the DASH diet can beneficially affect several cardiometabolic risk factors, as well as protect against CVD and T2D development. Further data is needed to clarify its efficacy in NAFLD/NASH biochemical and histological features.

Ketogenic diet and NAFLD

Low-carbohydrate ketogenic diets (KD) have been reported to significantly reduce intrahepatic TG content within 48 h in obese individuals.³⁴ Apart from weight loss, KD may decrease insulin levels and lipogenesis, as well as increase fatty acid oxidation (due to their very low carbohydrate content), and even beneficially affect liver pathology (due to the role of ketone bodies as moderators of fibrosis and inflammation).³⁵ Reduced hepatic insulin resistance and increased hepatic mitochondrial redox state, promoting the net hydrolysis of intrahepatic TG and thus ketogenesis from the resulting fatty acids, have also been implicated in KD-related NAFLD reversal.³⁶

In a pilot, open-label, randomized controlled trial involving 18 obese women with polycystic ovary syndrome, KD for 12 weeks was superior in lowering ALT and AST, and improving liver ultrasound features compared with the control group (receiving Essentiale plus Yasmin, i.e., conventional drug treatment).³⁷ Furthermore, a very low-calorie KD led to greater reductions in body weight, visceral adipose tissue and liver fat content compared with a standard low-calorie diet in 39 obese patients after 2 months of intervention.³⁸ The authors suggested that this rapid mobilization of hepatic fat and weight loss induced by KD could serve as an effective alternative for NAFLD treatment.³⁸ It has also been reported that obese men may experience larger benefits (in terms of body weight and liver tests reduction) with very low-carbohydrate KD compared with pre-menopausal women; these differences are lessened after menopause.³⁹

The implementation of a hypocaloric KD for 6.5 months was shown to significantly improve body weight, systolic BP, TG, ALT, AST and fibrosis score in 38 patients with NASH (diagnosed by liver biopsy, transient elastography, magnetic resonance elastography or liver test abnormalities).⁴⁰ However, long-term maintenance on a KD could lead to increases in liver tests and induce lipid and glucose disorders (due to their high-fat content) and thus increased vigilance and monitoring is encouraged in patients on such a diet.^{41,42} Overall, further clinical evidence is needed to establish the role (and ideal duration) of KD in NAFLD prevention and treatment.

Intermittent fasting diet and NAFLD

In an open-label randomized controlled trial, 74 patients with NAFLD (diagnosed by ultrasound, CT, MRI or transient elastography) were assigned in a 1:1:1 ratio to intermittent calorie restriction diet (the 5:2 diet), low-carb high-fat diet (LCHF) or general lifestyle advice (standard of care; SoC) and followed-up for 12 weeks.⁴³ Of note, participants in the 5:2 group were instructed to consume 600 kcal/day for men and 6500 kcal/day for women on 2 non-consecutive days per week. Both 5:2 and LCHF diets were superior to SoC treatment in terms of body weight and liver steatosis reduction (measured by MRS), leading to similar improvements.⁴³ Furthermore, the 5:2 diet (but not the LCHF diet) also reduced liver stiffness and LDL-C and was better tolerated than LCHF.⁴³

Periodic fasting was also shown to significantly reduce FLI in 697 individuals with or without T2D in a

prospective observational trial; the magnitude of this benefit was greater in T2D patients.⁴⁴ Body weight, BMI, waist circumference, fasting glucose, HbA1c and liver enzymes were also significantly decreased after periodic fasting. FLI improvement correlated with the number of fasting days and the extent of BMI reduction.⁴⁴ After fasting, almost half of the participants with baseline FLI ≥ 60 (representing the threshold for NAFLD) shifted to a lower category of FLI risk, thus suggesting liver disease reversion. It should be noted that periodic fasting was implemented as it follows: an initial phase of a low-calorie transition day (600 kcal/day mono-diet consisting of vegetables, fruits, oat or rice), followed by the fasting period (250 mL vegetable broth or fruit juice at midday, 250 mL vegetable broth in the evening and 20 g honey optionally), and then a stepwise reintroduction of food (lacto-ovo-vegetarian food increasing from 800 to 1800 kcal/day over at least 3 days).⁴⁴ The participants were advised to drink ≥ 2 L of water/day.

Alternate-day fasting was reported to significantly decrease insulin resistance, total cholesterol, LDL-C, liver weight and ALT in animal models of MetS.⁴⁵ Similarly, significant reductions in body weight, fat mass, total cholesterol and TG were observed among 271 patients with NAFLD (assessed by ultrasound) following alternate-day fasting or time-restricted feeding for 12 weeks.⁴⁶ In another randomized clinical trial, involving 43 patients with NAFLD (defined by elevated liver tests), alternate-day calorie restriction for 8 weeks significantly lowered BMI, ALT, liver steatosis grades and fibrosis scores compared with habitual diet.⁴⁷ Alternate-day diet was well-tolerated with good adherence rate throughout the study.⁴⁷

There is some evidence that Ramadan fasting can improve NAFLD features. In this context, among 83 NAFLD patients, body weight, BMI, waist circumference, waist-to-hip ratio and body fat percentage were significantly reduced in those who performed Ramadan fasting compared with the non-fasting group.⁴⁸ Significant improvements in liver tests, steatosis, inflammatory markers, insulin sensitivity and NAFLD severity scores have also been reported following Ramadan fasting in NAFLD/NASH patients.^{49,50}

A recent meta-analysis, including 6 studies (4 used Ramadan fasting and 2 used alternate-day fasting) with a total of 417 NAFLD patients, further supports the beneficial effects of intermittent fasting on body weight, BMI and liver tests.⁵¹ The authors concluded that long-term safety and feasibility of intermittent fasting should be evaluated in the future.⁵¹

Overall, further studies, including a control group and long-term follow-up, are needed to establish the positive effects of different types of intermittent fasting (e.g., 5:2, alternate-day, periodic and Ramadan fasting, as well as 16/8 involving 16 h fasting every day) on NAFLD development and progression.

Vegetarian (vegan) diet and NAFLD

A cross-sectional study, involving 2127 nonvegetarians and 1273 vegetarians (all healthy volunteers), showed that the odds for fatty liver (measured by ultrasound) were significantly lower (by 21%) in vegetarians compared with nonvegetarians, even after adjustment for gender, age, smoking, alcohol intake and education.⁵² However, BMI slightly

attenuated this association. Furthermore, nonvegetarians had a more severe fibrosis score than vegetarians.⁵² The authors suggested that the observed liver benefits from the vegetarian diet may be attributed to its rich content in polyphenols which can decrease inflammation, oxidative stress and insulin resistance, thereby suppressing NAFLD progression.⁵²

A previous analysis of data from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study ($n=892$ participants) reported that the consumption of a vegetarian diet was associated with lower BMI, fasting glucose, insulin resistance, total cholesterol and LDL-C, as well as a lower (by 57%) risk of fatty liver [assessed by CT].⁵³

In a 3-month randomized clinical trial with 75 overweight/obese NAFLD patients, lacto-ovo-vegetarian diet (based on eliminating poultry, meat and fish, but including eggs and dairy products) was compared with a standard weight-loss diet (based on the standard food pyramid, free in all sources of food).⁵⁴ Patients following the lacto-ovo-vegetarian diet showed greater improvements in body weight, BMI, waist circumference, ALT, fasting glucose, insulin resistance, TG, LDL-C and systolic BP, as well as a greater alleviation of NAFLD grade (in ultrasonography) compared with those on the weight-loss diet.⁵⁴

In another prospective, pilot study, 26 NAFLD patients followed a strict vegan diet (excluding all animal products) for 6 months.⁵⁵ At the end of the study, liver enzymes (ALT, AST, GGT) were significantly improved and even normalized in 20/26 patients. Of note, body weight and BMI were also significantly decreased but this reduction did not correlate with the normalization of liver tests, thus highlighting the fact that a vegan diet can beneficially affect liver function, irrespective of weight loss.⁵⁵

A previous cross-sectional, retrospective study ($n=615$) compared NAFLD prevalence (measured by ultrasound) between Buddhist priests (being vegetarians) and controls (matched for age, gender, BMI and presence/absence of MetS).⁵⁶ No difference was observed in NAFLD prevalence between the 2 groups, with Buddhist priests also having higher liver tests (ALT, AST) and TG levels.⁵⁶ The authors concluded that "The vegetarian diet does not protect against NAFLD", however such a statement seems too strong for such limited data and cannot be supported by these results.

Overall, healthy plant-based diets (as the vegetarian) were related to a lower NAFLD risk (defined by FLI) and more favorable liver tests as shown in cross-sectional study using data from the US National Health and Nutrition Examination Survey (NHANES).⁵⁷ Such dietary patterns (including Mediterranean, DASH and vegetarian diets) have been proposed for NAFLD/NASH management.⁵⁸ Further research should focus on the effects of the vegetarian diet and its subtypes (e.g., lacto-, ovo-, lacto + ovo-, pescatarian, vegan) on liver biochemistry and histology in NAFLD/NASH patients.

Paleo diet and NAFLD

Data on the effects of the paleo(lithic)-type diet (also known as the Hunter-Gatherer diet) in NAFLD/NASH patients is lacking. A single-blinded, randomized controlled, pilot study ($n=32$ individuals with ≥ 2 MetS features) found that a 2-week paleo diet significantly lowered body weight, BP,

Table 1 Beneficial effects of different dietary patterns on cardiometabolic and liver parameters observed in NAFLD patients.

Dietary pattern	Beneficial effects
Mediterranean diet	Body weight BMI BP Oxidative stress Inflammation Insulin resistance Fasting glucose Fasting lipids NAFLD score Intrahepatic fat content Liver tests Hepatic steatosis Liver stiffness Hepatic fibrosis NAFLD severity
Dietary Approaches to Stop Hypertension (DASH)	Body weight BMI Inflammation Insulin resistance Fasting lipids Fasting TG ALT Liver fat content
Vegetarian diet	Body weight BMI Waist circumference Systolic BP Fasting glucose Insulin resistance TG, LDL-C ALT Liver fat NAFLD grade
Ketogenic diet	Body weight Systolic BP Fasting TG Liver tests (ALT, AST) Liver fibrosis score Hepatic insulin resistance
Intermittent fasting diet	Body weight BMI Body fat mass Inflammation Insulin sensitivity Fasting total cholesterol and TG Liver tests (ALT, AST) Liver steatosis Hepatic stiffness Liver fibrosis NAFLD severity scores

Table 1 (Continued)

Dietary pattern	Beneficial effects
Paleo diet	Data in NAFLD patients are missing BMI Body fat mass Waist and hip circumference Waist/hip ratio BP Insulin resistance Fasting glucose Fasting lipids Liver fat


BMI: body mass index; BP: blood pressure; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; ALT: alanine transaminase; AST: aspartate transaminase; NAFLD: non-alcoholic fatty liver disease.

total cholesterol and TG, as well as increased HDL-C.⁵⁹ These effects could also be beneficial in NAFLD/NASH patients. Indeed, the paleolithic diet (based on vegetables, fruits, vegetables, nuts, roots and organ meats) has been reported to improve dyslipidemia, hypertension, body weight, waist circumference, fasting glucose and insulin resistance.^{60,61} In another randomized study, involving 70 healthy, obese, postmenopausal women, liver fat (assessed by proton MRS) was significantly lower in women following a paleo diet for 6 months compared with those on a low-fat diet.⁶² However, this difference in liver fat reduction lost its statistical significance at 24 months. Furthermore, the consumption of a paleo diet for 5 weeks led to a significant decrease in liver TG content (measured by proton MRS), as well as improvements in BMI, fasting glucose, BP, lipids, waist and hip circumference, waist/hip ratio and abdominal sagittal diameter in 10 healthy postmenopausal women.⁶³ Similarly, body weight and fat mass, as well as liver fat (assessed by MRS) were significantly reduced in 32 overweight-obese T2D patients that followed a paleolithic diet (with or without exercise) for 12 weeks.⁶⁴ Adipose and peripheral tissue (but not hepatic) insulin sensitivity was also improved.

Overall, the paleo diet seems a promising asset in preventing/treating NAFLD but well-designed, long-term, clinical trials are needed to elucidate the impact of this dietary pattern on biochemical and/or histological NAFLD/NASH parameters.

Table 1 summarizes the abovementioned beneficial effects of different dietary patterns on cardiometabolic and liver parameters observed in NAFLD patients. These diet-induced benefits could prevent/minimize CVD and liver morbidity/mortality (Fig. 1).

It should be noted that recently, have proposed a new definition of fatty liver has been proposed by several international expert panels, namely metabolic dysfunction-associated fatty liver disease (MAFLD).⁶⁵



NAFLD: non-alcoholic fatty liver disease; DASH: Dietary Approaches to Stop Hypertension; BMI: Body mass index; BP: blood pressure; WC: waist circumference

Figure 1 The role of diet in NAFLD treatment. NAFLD: non-alcoholic fatty liver disease; DASH: Dietary Approaches to Stop Hypertension; BMI: body mass index; BP: blood pressure; WC: waist circumference.

Conclusions

Currently, diet-induced weight loss is regarded as the first therapeutic approach in NAFLD/NASH to resolve steatosis and reverse fibrosis. Plant-based dietary patterns, poor in saturated fat, refined carbohydrates, red and processed meats, are preferred, including the Mediterranean, DASH and vegetarian/vegan diets.⁵⁸ Such dietary patterns have previously been recommended for the prevention and treatment of MetS.⁶⁶ Since NAFLD is considered as the hepatic manifestation of MetS,⁵ it follows that these diets can also be beneficial for NAFLD/NASH patients. MedDiet is regarded as the diet of choice for the prevention/treatment of NAFLD/NASH and its complications, based on the available evidence. Future well-designed clinical trials will establish the role of each of these dietary patterns, as well as of KD, intermittent fasting and paleo diets in NAFLD/NASH prevention and treatment.

Nevertheless, since psychological, social, cultural and economic factors, as well as co-morbidities may differ, there is no “one-size-fits-all” dietary intervention for NAFLD management. Clinicians should discuss the different dietary patterns with their patients and define the diet that each individual prefers and is able to implement in his/her daily life.

Conflict of interest

The authors declare that the current research was conducted independently, in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

NK has given talks, attended conferences and participated in trials sponsored by Angelini, Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, Mylan, Novo Nordisk, Sanofi and Servier.

APS is currently Vice President of Romanian National Diabetes Committee, and she has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies, including AstraZeneca,

Boehringer Ingelheim, Medtronic, Eli Lilly, Merck, Novo Nordisk, Novartis, Roche Diagnostics, and Sanofi.

MR is a full-time Professor of Internal Medicine at University of Palermo, Italy, and currently Section Editor in Chief for the International Journal of Molecular Sciences and Medical Director, Novo Nordisk in Eastern Europe; he has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies including Amgen, Astra Zeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi and Servier.

None of the above had any role in this article, which has been written independently, without any financial or professional help, and reflects only the authors’ opinion, without any role of the industry.

References

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64:73–84.
2. Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology*. 2019;69:2672–82.
3. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. *World J Gastroenterol*. 2015;21:6820–34.
4. Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, et al. Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. *Curr Vasc Pharmacol*. 2020;18:172–81.
5. Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? *Curr Vasc Pharmacol*. 2018;16:219–27.
6. Katsiki N, Athyros VG, Mikhailidis DP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. *J Diabetes Complications*. 2017;31:521–2.

7. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doulas M, Ganotakis ES, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. *Metabolism*. 2017;71:17–32.
8. Gomez-Delgado F, Katsiki N, Lopez-Miranda J, Perez-Martinez P. Dietary habits, lipoprotein metabolism and cardiovascular disease: from individual foods to dietary patterns. *Crit Rev Food Sci Nutr*. 2021;61:1651–69.
9. Schwingshackl L, Morze J, Hoffmann G. Mediterranean diet and health status: active ingredients and pharmacological mechanisms. *Br J Pharmacol*. 2020;177:1241–57.
10. Ditano-Vázquez P, Torres-Peña JD, Galeano-Valle F, Pérez-Caballero AI, Demelo-Rodríguez P, Lopez-Miranda J, et al. The fluid aspect of the Mediterranean diet in the prevention and management of cardiovascular disease and diabetes: the role of polyphenol content in moderate consumption of wine and olive oil. *Nutrients*. 2019;11:2833.
11. Katsiki N, Pérez-Martinez P, Lopez-Miranda J. Olive oil intake and cardiovascular disease prevention: ‘‘seek and you shall find’’. *Curr Cardiol Rep*. 2021;23:64.
12. Gotsis E, Anagnostis P, Mariolis A, Vlachou A, Katsiki N, Karagiannis A. Health benefits of the Mediterranean Diet: an update of research over the last 5 years. *Angiology*. 2015;66:304–18.
13. Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. *Nutrients*. 2021;13:1442.
14. Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. *World J Gastroenterol*. 2018;24:2083–94.
15. Gosal H, Kaur H, Chakwop Ngassa H, Elmenawi KA, Anil V, Mohammed L. The significance of the Mediterranean diet in the management of non-alcoholic fatty liver disease: a systematic review. *Cureus*. 2021;13:e15618.
16. Saavedra Y, Mena V, Priken K. Effect of the Mediterranean diet on histological indicators and imaging tests in non-alcoholic fatty liver disease. *Gastroenterol Hepatol*. 2021. S0210-5705(21)00204-1.
17. Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, et al. Mediterranean diet and NAFLD: what we know and questions that still need to be answered. *Nutrients*. 2019;11:2971.
18. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms. *Liver Int*. 2017;37:936–49.
19. Asbaghi O, Choghakhori R, Ashtary-Larky D, Abbasnezhad A. Effects of the Mediterranean diet on cardiovascular risk factors in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. *Clin Nutr ESPEN*. 2020;37:148–56.
20. Akhlaghi M, Ghasemi-Nasab M, Riasatian M. Mediterranean diet for patients with non-alcoholic fatty liver disease, a systematic review and meta-analysis of observational and clinical investigations. *J Diabetes Metab Disord*. 2020;19:575–84.
21. Kawaguchi T, Charlton M, Kawaguchi A, Yamamura S, Nakano D, Tsutsumi T, et al. Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review meta-analysis, and meta-regression analysis of randomized controlled trials. *Semin Liver Dis*. 2021;41:225–34.
22. Moosavian SP, Arab A, Paknahad Z. The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: a systematic review of randomized controlled trials. *Clin Nutr ESPEN*. 2020;35:40–6.
23. Pugliese N, Plaz Torres MC, Petta S, Valenti L, Giannini EG, Aghemo A. Is there an ‘ideal’ diet for patients with NAFLD? *Eur J Clin Invest*. 2021:e13659.
24. Glen J, Floros L, Day C, Pryke R. Guideline Development Group Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. *BMJ*. 2016;354:i4428.
25. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64:1388–402.
26. Soltani S, Shirani F, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials. *Obes Rev*. 2016;17:442–54.
27. Chiavaroli L, Vigiouliou E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, et al. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. *Nutrients*. 2019;11:338.
28. Parra-Vargas M, Rodríguez-Echevarria R, Jimenez-Chillaron JC. Nutritional approaches for the management of nonalcoholic fatty liver disease: an evidence-based review. *Nutrients*. 2020;12:3860.
29. Xiao ML, Lin JS, Li YH, Liu M, Deng YY, Wang CY, et al. Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and elderly adults. *Public Health Nutr*. 2020;23:674–82.
30. Hekmatdoost A, Shamsipour A, Meibodi M, Gheibzadeh N, Eslamparast T, Poustchi H. Adherence to the Dietary Approaches to Stop Hypertension (DASH) and risk of nonalcoholic fatty liver disease. *Int J Food Sci Nutr*. 2016;67:1024–9.
31. Park SY, Nouredin M, Boushey C, Wilkens LR, Setiawan VW. Diet quality association with nonalcoholic fatty liver disease by cirrhosis status: the multiethnic cohort. *Curr Dev Nutr*. 2020;4:nzaa024.
32. Watzinger C, Nonnenmacher T, Grafetstätter M, Sowah SA, Ulrich CM, Kauczor HU, et al. Dietary factors in relation to liver fat content: a cross-sectional study. *Nutrients*. 2020;12:825.
33. Razavi Zade M, Telkabadi MH, Bahmani F, Salehi B, Farshbaf S, Asemi Z. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. *Liver Int*. 2016;36:563–71.
34. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. *Gastroenterology*. 2009;136:1552–60.
35. Watanabe M, Tozzi R, Risi R, Tuccinardi D, Mariani S, Basciani S, et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: a comprehensive review of the literature. *Obes Rev*. 2020;21:e13024.
36. Luukkonen PK, Dufour S, Lyu K, Zhang XM, Hakkarainen A, Lehtimäki TE, et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. *Proc Natl Acad Sci U S A*. 2020;117:7347–54.
37. Li J, Bai WP, Jiang B, Bai LR, Gu B, Yan SX, et al. Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: a randomized, open-label, parallel-group, controlled pilot trial. *J Obstet Gynaecol Res*. 2021;47:1145–52.
38. Cunha GM, Guzman G, Correa De Mello LL, Trein B, Spina L, Buscade I, et al. Efficacy of a 2-month Very Low-Calorie Ketogenic Diet (VLCKD) compared to a standard low-calorie diet in reducing visceral and liver fat accumulation in patients with obesity. *Front Endocrinol (Lausanne)*. 2020;11:607.
39. D’Abbondanza M, Ministrini S, Pucci G, Nulli Migliola E, Martorelli EE, Gandolfo V, et al. Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: the role of sex differences. *Nutrients*. 2020;12:2748.

40. Belopolsky Y, Khan MQ, Sonnenberg A, Davidson DJ, Fimmel CJ. Ketogenic hypocaloric diet improves nonalcoholic steatohepatitis. *J Transl Int Med.* 2020;8:26–31.
41. Anekwe CV, Chandrasekaran P, Stanford FC. Ketogenic diet-induced elevated cholesterol elevated liver enzymes and potential non-alcoholic fatty liver disease. *Cureus.* 2020;12:e6605.
42. Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. *Curr Opin Clin Nutr Metab Care.* 2012;15:374–80.
43. Holmer M, Lindqvist C, Petersson S, Moshtaghi-Svensson J, Tillander V, Brismar TB, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial. *JHEP Rep.* 2021;3:100256.
44. Drinda S, Grundler F, Neumann T, Lehmann T, Steckhan N, Michalsen A, et al. Effects of periodic fasting on fatty liver index – a prospective observational study. *Nutrients.* 2019;11:2601.
45. Gamil NMB, El Agaty SM, Megahed GK, Mansour RS, Abdel-Latif MS. Reversion to regular diet with alternate day fasting can cure grade-I non-alcoholic fatty liver disease (NAFLD) in high-fructose-intake-associated metabolic syndrome. *Egypt Liver J.* 2021;11:60.
46. Cai H, Qin YL, Shi ZY, Chen JH, Zeng MJ, Zhou W, et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. *BMC Gastroenterol.* 2019;19:219.
47. Johari MI, Yusoff K, Haron J, Nadarajan C, Ibrahim KN, Wong MS, et al. A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease. *Sci Rep.* 2019;9:11232.
48. Aliasghari F, Izadi A, Gargari BP, Ebrahimi S. The effects of Ramadan fasting on body composition, blood pressure glucose metabolism, and markers of inflammation in NAFLD patients: an observational trial. *J Am Coll Nutr.* 2017;36:640–5.
49. Ebrahimi S, Gargari BP, Aliasghari F, Asjodi F, Izadi A. Ramadan fasting improves liver function and total cholesterol in patients with nonalcoholic fatty liver disease. *Int J Vitam Nutr Res.* 2020;90:95–102.
50. Mari A, Khoury T, Baker M, Said Ahmad H, Abu Baker F, Mahamid M. The impact of Ramadan fasting on fatty liver disease severity: a retrospective case control study from Israel. *Isr Med Assoc J.* 2021;23:94–8.
51. Yin C, Li Z, Xiang Y, Peng H, Yang P, Yuan S, et al. Effect of intermittent fasting on non-alcoholic fatty liver disease: systematic review and meta-analysis. *Front Nutr.* 2021;8:709683.
52. Chiu TH, Lin MN, Pan WH, Chen YC, Lin CL. Vegetarian diet, food substitution, and nonalcoholic fatty liver. *Ci Ji Yi Xue Za Zhi.* 2018;30:102–9.
53. Jin Y, Kanaya AM, Kandula NR, Rodriguez LA, Talegawkar SA. Vegetarian diets are associated with selected cardiometabolic risk factors among middle-older aged south Asians in the United States. *J Nutr.* 2018;148:1954–60.
54. Garousi N, Tamizifar B, Pourmasoumi M, Feizi A, Askari G, Clark CCT, et al. Effects of lacto-ovo-vegetarian diet vs. standard-weight-loss diet on obese and overweight adults with non-alcoholic fatty liver disease: a randomised clinical trial. *Arch Physiol Biochem.* 2021:1–9.
55. Chiarioni G, Popa SL, Dalbeni A, Senore C, Leucuta DC, Baroni L, et al. Vegan diet advice might benefit liver enzymes in non-alcoholic fatty liver disease: an open observational pilot study. *J Gastrointest Liver Dis.* 2021;30:81–7.
56. Choi SH, Oh DJ, Kwon KH, Lee JK, Koh MS, Lee JH, et al. A vegetarian diet does not protect against nonalcoholic fatty liver disease (NAFLD): a cross-sectional study between Buddhist priests and the general population. *Turk J Gastroenterol.* 2015;26:336–43.
57. Mazidi M, Kengne AP. Higher adherence to plant-based diets are associated with lower likelihood of fatty liver. *Clin Nutr.* 2019;38:1672–7.
58. Hydes TJ, Ravi S, Looma R, Gray EM. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. *Clin Mol Hepatol.* 2020;26:383–400.
59. Boers I, Muskiet FA, Berkelaar E, Schut E, Penders R, Hoenderdos K, et al. Favourable effects of consuming a Palaeolithic-type diet on characteristics of the metabolic syndrome: a randomized controlled pilot-study. *Lipids Health Dis.* 2014;13:160.
60. Tarantino G, Citro V, Finelli C. Hype or reality: should patients with metabolic syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) diet to decrease morbidity? *J Gastrointest Liver Dis.* 2015;24:359–68.
61. Manheimer EW, van Zuuren EJ, Fedorowicz Z, Pijl H. Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis. *Am J Clin Nutr.* 2015;102:922–32.
62. Otten J, Mellberg C, Ryberg M, Sandberg S, Kullberg J, Lindahl B, et al. Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention. *Int J Obes (Lond).* 2016;40:747–53.
63. Ryberg M, Sandberg S, Mellberg C, Stegle O, Lindahl B, Larsson C, et al. A Palaeolithic-type diet causes strong tissue-specific effects on ectopic fat deposition in obese postmenopausal women. *J Intern Med.* 2013;274:67–76.
64. Otten J, Stomby A, Waling M, Isaksson A, Söderström I, Ryberg M, et al. A heterogeneous response of liver and skeletal muscle fat to the combination of a Paleolithic diet and exercise in obese individuals with type 2 diabetes: a randomised controlled trial. *Diabetologia.* 2018;61:1548–59.
65. Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: renovation of clinical practice and disease awareness of fatty liver. *Hepatol Res.* 2021, <http://dx.doi.org/10.1111/hepr.13706> [Epub ahead of print].
66. Pérez-Martínez P, Mikhailidis DP, Athyros VG, Bullo M, Couture P, Covas MI, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. *Nutr Rev.* 2017;75:307–26.